We are live on ! Find out more
DFTX

Definium Therapeutics

104 hedge funds and large institutions have $18M invested in Definium Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

388% more call options, than puts

Call options by funds: $6.76M | Put options by funds: $1.39M

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

48% more capital invested

Capital invested by funds: $12.1M → $18M (+$5.82M)

21% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 19

12% more funds holding

Funds holding: 93104 (+11)

2.48% more ownership

Funds ownership: 9.76%12.24% (+2.5%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
104
Holders Change
+11
Holders Change %
+11.83%
% of All Funds
1.52%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
23
Reduced
19
Closed
9
Calls
$6.76M
Puts
$1.39M
Net Calls
+$5.37M
Net Calls Change
+$368K

DFTX Hedge Fund Activity: Q4 2023 in Review

104 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q4 2023, worth a combined $18M — up 48% from $12.1M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new DFTX positions and 9 closed out — a net gain of 12 holders — while 23 added to existing stakes and 19 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.81M. The largest seller was Millennium Management, cutting an estimated $390K.

  • 104 institutional investors held Definium Therapeutics (DFTX) as of Q4 2023, up from 93 in Q3 2023.
  • Funds reported $18M of Definium Therapeutics stock for Q4 2023, up 48% quarter-over-quarter.
  • 21 funds opened new Definium Therapeutics positions in Q4 2023 and 9 closed out, a net change of +12 holders.
  • The largest Definium Therapeutics buyer in Q4 2023 was Ikarian Capital, an estimated $1.81M added.
  • The largest Definium Therapeutics seller in Q4 2023 was Millennium Management, an estimated $390K sold.

Based on aggregated 13F filings for Q4 2023.